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Worldwide, Shigellosis is a significant public health issue, associated with nearly one million deaths annually. About half a million
cases of Shigella infection are reported annually in theUnited States. Shigella bacteremia is uncommonand generally seen in children
and immunocompromised adults. We present a case of a Shigella sonnei bacteremia with marked hepatic derangement in a 27-year-
old previously healthy homosexual male with history of Roux-en-Y gastric bypass, who presented to the emergency room with a
4-day history of loose watery stool, abdominal cramps, nausea and vomiting, and yellow skin of 2-day duration. He reports similar
diarrhea illness in two close contacts in preceding days. On examination, he was fully oriented but dehydrated, icteric, and febrile.
Laboratory data revealedWBC of 2200/𝜇L, elevated AST and ALT (201 IU/L, 73 IU/L resp.), normal alkaline phosphatase, elevated
total and direct bilirubin of 8.2mg/dL and 4.4mg/dL, albumin of 3.2 g/dL, INR of 2.9, prothrombin time of 31.7, and platelet of
96,000/𝜇L. Workup for infectious, autoimmune and medication-induced hepatitis, Wilson’s disease, and hemochromatosis was
negative. Abdominal ultrasound and computed tomography of the abdomen showed hepatic steatosis and right-sided colitis. Stool
and blood cultures were positive for Shigella sonnei. He was treated with ciprofloxacin with improvement in liver function. Follow-
up blood test 4 months later was within normal limits.
1. Introduction
Worldwide, Shigella is a common food-borne bacterial cause
of dysentery and rarely causes bacteremia in the immuno-
compromised host [1, 2]. Infection is more common in
developing countries and areas with poor hygiene and con-
taminated water sources, but sexual transmission has been
reported among men who have sex with men (MSM) [1, 3–
6]. We report a case of Shigella bacteremia in a homosexual
male complicated by hepatic dysfunction.
2. Case Report
A 27-year-old African American male with a history of
morbid obesity status post-Roux-en-Y gastric bypass 9 years
prior presented with painful nonbloody mucoid diarrhea,
icterus, and dark urine of four-day duration. He described
recent travel with family to a beach resort in the United
States during which he noted that two family members had
developed a self-limited diarrheal illness. Three days after
exposure, he noted abdominal cramps followed by hourly
watery yellow stools without blood. He also had intermittent
nausea and an episode of bilious vomiting and reports not
eating since onset of diarrheal illness. He noticed a 17-pound
weight loss over 1 week. He had no fevers, chills, or rash.
There was no preceding history of eating uncooked fish
or meats and he had no tick exposure. Medication history
included Lisinopril and Amlodipine, and he denied any new
medications or alcohol use. He admitted to homosexual
intercourse.
He was acutely ill-looking with icteric sclera and dry
mucus membranes. Vitals signs showed low-grade fever of
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100.2∘F and pulse rate of 126 beats per minute. Cardiac,
lung, and skin examinations were unremarkable. Abdomen
was diffusely tender with hyperactive bowel sounds without
peritoneal signs.
Laboratorydatawas remarkable for leukopenia of 2200/𝜇L,
hemoglobin of 12.7 g/dL, normal platelet of 158,000/𝜇L,
sodium of 128meq/L and potassium of 3.2meq/L, acute
kidney injury with creatinine of 1.59mg/dL (baseline of
0.63mg/dL), BUN of 41mg/dL, and anion gap of 19. After
intravenous hydration, hemoglobin dropped to 10.1 g/dL and
platelet to 96,000/𝜇L. Sodium, BUN, and creatinine also
improved with rehydration. He was also noted to have ele-
vated transaminases AST 201 IU/L and ALT 73 IU/L, elevated
total bilirubin of 8.2mg/dL, direct bilirubin of 4.4mg/dL,
normal alkaline phosphatase of 66 IU/L, albumin of 3.2 g/dL,
normal lipase of 40U/L, and elevated lactate of 3.5meq/L.
INR was elevated to 1.8; however, he had normal haptoglobin
236mg/dL (36–195mg/dL) and LDH 177 IU/L (normal: 94–
202 IU/L). Hepatitis panel was negative. Patient also tested
negative for HIV, CMV, EBV, and Parvovirus B19 infec-
tion. Tylenol level was normal. Urinalysis showed moderate
bilirubinuria. Stool study was positive for Shigella sonnei
but was otherwise negative for bacteria, ova, or parasites.
Rickettsia rickettsii IgM was positive and he was treated with
Doxycycline. Other workup for tick-borne infection includ-
ing Lyme, Babesia, Ehrlichia, and Anaplasma was negative.
Autoimmune workups including ANA, antismooth muscle,
liver/kidney microsome, and mitochondrial antibodies were
negative. Alpha-1 antitrypsin and ceruloplasmin were also
normal.
Abdominal ultrasound showed a diffusely increased het-
erogeneous liver echogenicity with underlying hepatomegaly
consistent with hepatic steatosis. Hepatoportal duplex sho-
wed patent portal vein and hepatic artery. Computed tomog-
raphy of the abdomen and pelvis was significant for hepatic
steatosis, hepatomegaly, mild right colitis, and absence of
gallstones. Magnetic resonance cholangiopancreatography
(MRCP) was unremarkable with normal intra- and extrahep-
atic biliary tree.
Duringhishospital course, bilirubin trended up to 9mg/dL
and INR peaked at 2.9. Patient was not encephalopathic.
Given impending hepatic failure, recommendationwasmade
to transfer the patient to a transplant center but he declined.
He was treated with N-acetylcysteine. Blood culture initially
reported as Gram-negative rods presumptively Escherichia
coli (E. coli) was later confirmed to be Shigella sonnei. Urine
culture remained negative. He was treated with ciprofloxacin
based on sensitivity results with an improvement in diar-
rhea frequency and downward trend in transaminases. He
remained stable and was discharged home on Day 8. He was
doing well 4 months later with normal cell counts, normal
liver, and kidney function.
3. Discussion
Shigella has a low infectious dose, requiring as low as 10
organisms for infection, and it is easily transmitted from
person to person [20]. Outbreaks are common in day care
centers, institutions, and urban areas with crowded living
conditions [6]. In the United States and other developed
countries, transmission is usually fecal-oral from symp-
tomatic patient and fecal contamination of raw vegetable has
been identified in outbreaks [3, 6]. Average incubation period
is three days and patients typically presentswith small volume
watery to mucoid diarrhea, abdominal pain, vomiting, fever,
and bloody diarrhea.
Shigella sonnei is responsible for three-quarters of all cases
in theUS,while Shigella flexneri is predominant in developing
countries [1, 21, 22]. Complications range from rare intestinal
complications of toxic megacolon, intestinal obstruction to
systemic complications of hypovolemia, seizures, hypona-
tremia, and leukemoid reaction.
This case is unique for several reasons, first because
Shigella bacteremia is uncommon in adults and even less
common in the absence of underlying immunosuppression
[23, 24]. Our patient was not immunocompromised and
extensive workup to detect underlying predisposition was
negative. Patient did have a history of Roux-en-Y gas-
tric bypass and possibility of underlying nutritional defi-
ciency cannot be conclusively excluded. Morduchowicz et
al. reported 27 cases of Shigella bacteremia of which 16 had
an underlying predisposing condition [12]. Appannanavar et
al. also reported a case of bacteremia in a renal transplant
patient and two other cases in postrenal transplant are
reported in literature [8, 25, 26]. Hawkins et al. presented
a total of 9 cases of Shigella bacteremia in adults with
underlying predisposing comorbidities including the use of
immunosuppressant, diabetes mellitus, alcohol liver disease,
HIV/AIDS, and malignancy [16]. Similar to our case, Huynh
et al. presented an otherwise healthy male without identified
comorbidities; he was a MSM [19].
Increasing cases of Shigellosis have been reported among
MSM [4, 19]. In a case series of 466 cases of Shigella
bacteremia, two-thirds of reported cases in adult males were
in MSM [19]. Outbreak of Shigella among MSM has also
been reported in Europe, USA, and Australia [27–31]. There
is no increase in incidence of Shigella bacteremia amongHIV
infected individuals, although increased mortality has been
noted in HIV-positive patients with Shigella bacteremia [1].
Additionally, to our knowledge, this is the first reported
case of hepatic manifestation of Shigellosis in an adult. Our
patient had coagulopathy with bilirubinemia, elevated tra-
nsaminases, and thrombocytopenia but was not encephalo-
pathic and thus not by definition in fulminant liver failure.
Workup for viral hepatitis, toxin or drug hepatitis, autoim-
mune hepatitis, Wilson’s disease, malignant, or vascular eti-
ology was negative in the setting of Shigella bacteremia.
His underlying fatty liver disease might have played a role.
Despite the absence of encephalopathy, our patient was con-
sidered for referral to transplant center given rising bilirubin
and INR concerning for impending fulminant hepatic failure.
Guided by evidence of increased transplant free survival in
hepatic failure, he was treated with N-acetylcysteine when
he declined transfer. Of note, liver function improved with
treatment of Shigella infection. A case of fulminant hepatic
failure in a three-and-a-half-year-old boy with Shigella bac-
teremia also made clinical and biochemical improvement
with Shigellosis treatment [32].
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Table 1: Reported cases of adult Shigella sonnei bacteremia.
Author Comorbidity Outcome
Winter and Harding 1962 [7] None Recovery
Netter et al., 1974 [8] Renal transplant Recovery
O’Connor and O’Callaghan 1981 [9] Marrow Aplasia Death
Roncoroni et al., 1984 [10] (1) CKD Recovery
(2) None Death
Alkan et al., 1985 [11] Metastatic adenocarcinoma Death
Morduchowicz et al., 1987 [12] (1) None Recovery
(2) Diabetes mellitus Recovery
Dronda et al., 1988 [2] Diabetes mellitus Recovery
Christensen et al., 1990 [13] Congenital antithrombin III deficiency, postsplenectomy Recovery
Seymour et al., 1994 [14] (1) AIDS Death
(2) Alcoholic liver disease Recovery
Kenet et al., 1994 [15] Metastatic breast cancer Death
Hawkins et al., 2007 [16] (1) Multiple myeloma Recovery
(2) Diabetes mellitus Recovery
Liu et al., 2009 [17] Lung cancer Death
Markham et al., 2012 [18] AIDS Recovery
Huynh et al., 2015 [19] None Recovery
Our patient tested positive for Rickettsia rickettsii IgM
and this was considered to be a false positive result in
the absence of prominent fever and classical rash which
is seen in 90% of cases. Also our patient did not have
other common features of Rocky Mountain spotted fever
(RMSF) including headaches, myalgia, and arthralgia and no
preceding tick exposure. In advance cases of RMSF, elevations
in serum aminotransferases and bilirubin and prolongation
of prothrombin time are possible; it was however considered
an unlikely explanation in our index case. False positive
Rickettsia IgM is known to occur in presence of other bacteria
pathogen due to cross reactivity to similar lipopolysaccharide
[33, 34].
Huynh et al. reported a case of Shigella bacteremia in
34-year-old MSM in which a positive blood culture was
initially reported as E. coli [19]. E. coli and Shigella both
Enterobacteriaceae are genomically similar with identical O-
antigens and similar virulence determinants [35, 36]. Rapid
testing methods such as the natrix-assisted laser desorption
ionization-time of flight mass spectrometry (MALDI-TOF
MS) used in many diagnostic microbiology laboratories
cannot distinguish between both [37, 38]. In patients with
discordant Shigella stool culture and E. coli bacteremia,
conventional and serologic testing is required to correctly
identify Shigella and prevent an unnecessary search for an
additional infection source.
We found 18 reported adult cases of Shigella sonnei
bacteremia in literature. 14 of the 18 patients had an under-
lying immunocompromising comorbidity including diabetes
mellitus, AIDS, malignancy, and postorgan transplantation
(Table 1). One of the 4 patients without an identified comor-
bidity was a MSM similar to our case. All 3 patients with
underlying solid organ malignancy died during the course of
Shigella bacteremia. Over all, there were 6 deaths, 5 of which
had significant underlying comorbidities.
Shigellosis is often self-limited and infection tends to
clear spontaneously in most individuals. In severe cases with
complications, including bacteremia, treatment is indicated.
First-line treatment is with fluoroquinolones. However, given
increasing antibiotic resistance, particularly strains acquired
from Asia and Africa, susceptibility testing is important [3,
39, 40]. Of note, reduced susceptibility and/or resistance to
ciprofloxacin has been reported in the United States [21].
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